Other languages TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Market Closed - Nasdaq Other stock markets 21:00:00 17/06/2024 BST			5-day change	1st Jan Change
1.34 ^USD	+6.35%		+24.07%	-61.74%

06-11	TRACON Pharmaceuticals, Inc. Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for Trc102, A Dna Damage Repair Inhibitor, in Recurrent Glioblastoma Patients	CI
05-14	TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TRACON Pharmaceuticals, Inc. Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for Trc102, A Dna Damage Repair Inhibitor, in Recurrent Glioblastoma Patients	06-11
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14
Tracon Pharmaceuticals, Inc. Appoints David Lazar as Chief Business Development Officer	05-13
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	04-03
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	12-20
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	11-20
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	11-20
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	11-10
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	11-10
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	11-10
Top Premarket Gainers	11-10
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
TRACON Pharmaceuticals, Inc. Announces Resignation of Bonne Adams as Chief Operating Officer, Effective October 15, 2023	06/10/23
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned	18/09/23
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial	20/06/23
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23
Sector Update: Health Care Stocks Declining Late Tuesday	25/04/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Other languages

Filters